CDK5 knockdown suppresses the viability of MM cells and sensitizes them to bortezomib, a proteasome inhibitor that generates considerable clinical response in newly diagnosed as well as advanced multiple myeloma patients [113]. This evidence concerns the gene CDK5 and plasma cell myeloma.